Posted by Michael Wonder on 20 Sep 2021
Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance, which represents an agreement in principle regarding the public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis.
This is an extension of the letter of intent with the pan-Canadian Pharmaceutical Alliance including Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor).
